TSN222 in Subjects With Advanced Solid Tumors or Lymphomas — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas — Stella

Home/Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Fudan Cancer Hospital, Shanghai, Shanghai Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Tyligand Bioscience (Shanghai) Limited

Enrollment target

~162 participants

Started

July 2023

Primary completion

June 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.